

In-transit melanoma advance is difficult to predict

April 15 2013




Image courtesy of Blausen Medical

Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities, according to a study published online April 3 in *JAMA Surgery*.

(HealthDay)—Progressive disease cannot be reliably predicted by patient, clinical, or procedural factors in patients receiving regional therapy for advanced melanoma of the extremities, according to a study published online April 3 in *JAMA Surgery*.

Michael E. Lidsky, M.D., and colleagues from Duke University Medical Center in Durham, N.C. analyzed data from 215 in-transit [melanoma](#) patients who had undergone first-time regional therapy by either [melphalan](#)-based isolated limb infusion (ILI, 134 patients) or melphalan-based hyperthermic isolated limb perfusion (HILP, 81 patients).

The researchers found that in the ILI group, 32.1 percent had

[progressive disease](#) and 29.9 percent had a complete response. In the HILP group, 11.1 percent had progressive disease and 44.4 percent had a complete response. For patients with in-field progressive disease, median survival was 20.3 months for the ILI group and 15.0 months for the HILP group. Younger patients were at greater risk of progressive disease in the ILI group (odds ratio, 1.06) while no clinically relevant preoperative factors were identified predicting progressive disease in the HILP group. Procedural variables were not predictors of in-field progressive disease after ILI or HILP.

"Patient, clinical, and procedural factors are unreliable predictors of in-field progressive disease after regional therapy in patients with in-transit melanoma," Lidsky and colleagues conclude.

One author reported [financial relationships](#) with drug companies.

More information: [Abstract](#)

[Full Text \(subscription or payment may be required\)](#)

[Editorial \(subscription or payment may be required\)](#)

[Health News](#) Copyright © 2013 [HealthDay](#). All rights reserved.

Citation: In-transit melanoma advance is difficult to predict (2013, April 15) retrieved 7 May 2024 from <https://medicalxpress.com/news/2013-04-in-transit-melanoma-advance-difficult.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--